-
Super-Enhancer Hijacking of LINC01977 Drives LUAD via TGF-β/
2026-04-25
Zhang et al. (2022) reveal that super-enhancer-driven activation of the lncRNA LINC01977 promotes early-stage lung adenocarcinoma (LUAD) progression by amplifying canonical TGF-β/SMAD3 signaling. Their integrative study details the mechanistic feedback loop between tumor-associated macrophages, TGF-β microenvironment, and epigenetic regulation, highlighting new therapeutic targets in LUAD biology.
-
iPSC-Derived Multilineage Organoids Advance HEV Research Mod
2026-04-24
This study establishes induced pluripotent stem cell (iPSC)-derived liver, intestinal, and brain organoids as robust, physiologically relevant models for hepatitis E virus (HEV) infection, supporting replication of multiple clinical genotypes. The platform uncovers new aspects of HEV tropism and pathogenesis, providing a critical tool for virology studies and preclinical antiviral drug evaluation.
-
A 83-01: Optimizing ALK-5 Inhibitor Use in Organoid Research
2026-04-24
A 83-01 (ALK inhibitor) from APExBIO empowers researchers to precisely modulate TGF-β signaling, enabling breakthroughs in organoid modeling and EMT studies. This guide provides actionable workflows, troubleshooting strategies, and protocol enhancements to maximize the impact of this selective ALK-5 inhibitor in advanced cell biology.
-
ESCO2 Drives HCC Proliferation via PI3K/AKT/mTOR Pathway Act
2026-04-23
This study establishes ESCO2 as a key promoter of hepatocellular carcinoma (HCC) proliferation through activation of the PI3K/AKT/mTOR signaling pathway. The findings offer mechanistic insight into how ESCO2 accelerates cell cycle progression and inhibits apoptosis in HCC, highlighting its potential as a therapeutic target and underscoring the value of precise cell proliferation assays in cancer research.
-
Sorafenib (BAY-43-9006): Mechanistic Insights Reshaping Hepa
2026-04-23
Explore the multifaceted role of Sorafenib in cancer biology research, with an emphasis on its mechanistic impact in hepatocellular carcinoma models. This article delivers a unique comparative analysis and protocol guidance for advanced oncology investigations.
-
HyperScript III RT SuperMix: Precision Gene Expression by qP
2026-04-22
HyperScript III RT SuperMix streamlines reverse transcription and genomic DNA removal, delivering high-fidelity cDNA even from low-concentration or high-GC content RNA. This enables reproducible, quantitative gene expression analysis in challenging cancer research workflows, as highlighted by recent CRC immune marker discoveries.
-
Myriocin: Precision Serine Palmitoyltransferase Inhibitor fo
2026-04-22
Myriocin stands out as a gold-standard serine palmitoyltransferase inhibitor, delivering reproducible and selective control over sphingolipid metabolism in cancer, immunology, and cell cycle studies. This guide translates bench-proven protocols, advanced applications, and common troubleshooting strategies into actionable insights for researchers seeking robust results.
-
Antipyrine in Blood-Brain Barrier and CNS Drug Research
2026-04-21
High-purity Antipyrine unlocks reproducible, high-throughput blood-brain barrier permeability and CNS drug development workflows. Learn how to optimize experimental protocols, troubleshoot common pitfalls, and leverage reference models for robust pharmacokinetic and drug metabolism research.
-
A Novel Culture Paradigm Prolongs Mouse Corneal Epithelial C
2026-04-21
This study introduces a 6C medium that significantly extends the proliferative capacity of mouse corneal epithelial cells (mCECs) by integrating six targeted pathway inhibitors, including the ALK5 inhibitor SB 431542. The approach combats epithelial-mesenchymal transition, facilitating higher-yield, feeder-free cultures and unlocking new potential for regenerative ophthalmic research and transplantation.
-
LY2109761: Precision Disruption of TGF-β Signaling in Tumor
2026-04-20
Explore the advanced role of LY2109761, a TGF-β receptor type I and II dual inhibitor, in modulating cancer cell plasticity and stemness. This article uniquely bridges mechanistic insights with practical guidance for translational research.
-
Selective Spectrophotometric Determination of Phenolic β-Lac
2026-04-20
This study introduces two rapid, selective spectrophotometric methods for quantifying phenolic β-lactam antibiotics, including amoxicillin and its combinations with dicloxacillin, in pharmaceutical forms. The findings enable routine, interference-resistant quality control for complex antibiotic formulations, with broader implications for assay optimization in Gram-positive bacterial infection research.
-
Discovery and Characterization of MK 0893: A Potent Glucagon
2026-04-19
This study details the discovery and optimization of MK 0893, a selective, orally bioavailable glucagon receptor antagonist with nanomolar potency. The paper provides in-depth characterization of its binding, selectivity, and efficacy in preclinical models, positioning MK 0893 as a key tool for investigating glucose regulation in type 2 diabetes.
-
JNJ-26854165 (Serdemetan): HDM2 Antagonist for Cancer Resear
2026-04-18
JNJ-26854165 (Serdemetan) is a potent small molecule HDM2 antagonist with validated anti-proliferative and apoptosis-inducing effects in p53 wild-type tumor models. Its efficacy is supported by in vitro IC50 data and in vivo radiosensitization studies. This article provides structured evidence, protocol guidance, and best practices for advanced cancer research applications.
-
hiPSC-Derived Intestinal Organoids in Pharmacokinetic Modeli
2026-04-17
This study presents a streamlined, direct 3D culture protocol for deriving intestinal organoids from human pluripotent stem cells, enabling long-term propagation and differentiation into mature intestinal epithelial cell types. The resulting organoid-derived enterocytes exhibit key drug-metabolizing and transporter activities, offering a physiologically relevant in vitro platform for pharmacokinetic research and drug absorption studies.
-
Structural Mechanisms of FADD–Procaspase-8–cFLIP Complexes i
2026-04-16
This study provides the first atomic-level structures of human FADD–procaspase-8–cFLIP complexes, elucidating how these assemblies drive apoptotic and necroptotic signaling. The findings clarify death-effector domain (DED) assembly mechanisms, offering a structural framework to inform targeted apoptosis pathway activation in cancer research.